rss
Br J Ophthalmol 2008;92:70-73 doi:10.1136/bjo.2007.122283
  • Original Article
    • Clinical science

Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy

  1. F Gomi,
  2. M Sawa,
  3. H Sakaguchi,
  4. M Tsujikawa,
  5. Y Oshima,
  6. M Kamei,
  7. Y Tano
  1. Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  1. Fumi Gomi, Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; fgomi{at}ophthal.med.osaka-u.ac.jp
  • Accepted 3 June 2007
  • Published Online First 13 June 2007

Abstract

Aims: The aim of the study was to assess the short-term efficacy of intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV).

Methods: Intravitreal bevacizumab (1 mg) was injected into 11 eyes of 11 patients with PCV in this retrospective, interventional case series. The main outcome measure was the change in the polypoidal vessels on indocyanine green angiography (IA) 3 months after injection. The foveal height determined by optical coherence tomography and the best-corrected visual acuity (BCVA) also were evaluated before and after treatment.

Results: At baseline, subretinal fluid was observed in five eyes and a pigment epithelial detachment in eight eyes. The foveal height 1 month after injection decreased significantly (p = 0.023), but at 3 months, no significant decrease was observed, although an additional injection was administrated in five of 11 eyes. The IA at 3 months showed resolution of polyps in one eye but residual or enlarged lesions in the other ten eyes. The BCVA did not improve significantly, although the subjects had relatively good BCVA at baseline (mean 0.45).

Conclusion: Intravitreal injection of bevacizumab may reduce the fluid from PCV but seems to be ineffective for diminishing its choroidal vascular changes.

Footnotes

  • Funding: The authors have no proprietary interest in any aspect of this report.

  • Competing interests: None.

Responses to this article

  • Bevacizumab for polypoidal vasculopathy should be evaluated in a cross cultural population
    • Shree K Kurup,
    • Mehdi Ghajarnia
    Br J Ophthalmol published online August 8, 2009

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.122283v1
    2. bjo.2007.122283v2
    3. 92/1/70 most recent

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.